89 related articles for article (PubMed ID: 32956819)
1. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation.
Epperla N; Ahn KW; Khanal M; Litovich C; Ahmed S; Ghosh N; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
Transplant Cell Ther; 2021 Jan; 27(1):58-66. PubMed ID: 32956819
[TBL] [Abstract][Full Text] [Related]
2. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
[TBL] [Abstract][Full Text] [Related]
3. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
[TBL] [Abstract][Full Text] [Related]
4. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
5. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
Jiang JL; Gao WH; Wang LN; Wan M; Wang L; Hu J
Transplant Cell Ther; 2023 Aug; 29(8):512.e1-512.e8. PubMed ID: 37263418
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11.
Sakashita K; Yoshida N; Muramatsu H; Ohtsuka Y; Watanabe K; Yabe M; Kakuda H; Honda Y; Watanabe T; Haba M; Ohmori S; Matsuda K; Yuza Y; Saito A; Horibe K; Adachi S; Manabe A
Transplant Cell Ther; 2024 Jan; 30(1):105.e1-105.e10. PubMed ID: 37806448
[TBL] [Abstract][Full Text] [Related]
7. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
Joseph J; Srour SA; Milton DR; Ramdial JL; Saini NY; Olson AL; Bashir Q; Oran B; Alousi AM; Hosing C; Qazilbash MH; Kebriaei P; Shpall EJ; Champlin RE; Popat UR
Transplant Cell Ther; 2023 Dec; 29(12):770.e1-770.e6. PubMed ID: 37742746
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.
Munshi PN; Chen Y; Ahn KW; Awan FT; Cashen A; Shouse G; Shadman M; Shaughnessy P; Zurko J; Locke FL; Goodman AM; Bisneto JCV; Sauter C; Kharfan-Dabaja MA; Meyers G; Jaglowski S; Herrera A; Hamadani M
Transplant Cell Ther; 2022 Aug; 28(8):487.e1-487.e7. PubMed ID: 35609865
[TBL] [Abstract][Full Text] [Related]
9. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity.
Fitch T; Lane A; McDonnell J; Bleesing J; Jordan M; Kumar A; Khandelwal P; Khoury R; Marsh R; Chandra S
Transplant Cell Ther; 2024 Jan; 30(1):101.e1-101.e12. PubMed ID: 37821080
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M
Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
Murthy HS; Zhang MJ; Chen K; Ahmed S; Deotare U; Ganguly S; Kansagra A; Michelis FV; Nishihori T; Patnaik M; Abid MB; Aljurf M; Arai Y; Bacher U; Badar T; Badawy SM; Ballen K; Battiwalla M; Beitinjaneh A; Bejanyan N; Bhatt VR; Brown VI; Martino R; Cahn JY; Castillo P; Cerny J; Chhabra S; Copelan E; Daly A; Dholaria B; Diaz Perez MA; Freytes CO; Grunwald MR; Hashmi S; Hildebrandt GC; Jamy O; Joseph J; Kanakry CG; Khera N; Krem MM; Kuwatsuka Y; Lazarus HM; Lekakis LJ; Liu H; Modi D; Munshi PN; Mussetti A; Palmisiano N; Patel SS; Rizzieri DA; Seo S; Shah MV; Sharma A; Sohl M; Solomon SR; Ulrickson M; Ustun C; van der Poel M; Verdonck LF; Wagner JL; Wang T; Wirk B; Zeidan A; Litzow M; Kebriaei P; Hourigan CS; Weisdorf DJ; Saber W; Kharfan-Dabaja MA
Blood Adv; 2023 Nov; 7(22):7007-7016. PubMed ID: 37792849
[TBL] [Abstract][Full Text] [Related]
12. Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.
Walter RB; Sandmaier BM; Othus M; Orvain C; Rodríguez-Arbolí E; Oshima MU; Schoch G; Davis C; Joachim Deeg H; Storb R
Bone Marrow Transplant; 2023 Apr; 58(4):377-385. PubMed ID: 36577856
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT.
Rovó A; Gras L; Piepenbroek B; Kröger N; Reinhardt HC; Radujkovic A; Blaise D; Kobbe G; Niityvuopio R; Platzbecker U; Sockel K; Hunault-Berger M; Cornelissen JJ; Forcade E; Bourhis JH; Chalandon Y; Kinsella F; Nguyen-Quoc S; Maertens J; Elmaagacli A; Mordini N; Hayden P; Raj K; Drozd-Sokolowska J; de Wreede LC; McLornan DP; Robin M; Yakoub-Agha I; Onida F
Am J Hematol; 2024 Feb; 99(2):203-215. PubMed ID: 38009469
[TBL] [Abstract][Full Text] [Related]
14. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.
Boyiadzis M; Zhang MJ; Chen K; Abdel-Azim H; Abid MB; Aljurf M; Bacher U; Badar T; Badawy SM; Battiwalla M; Bejanyan N; Bhatt VR; Brown VI; Castillo P; Cerny J; Copelan EA; Craddock C; Dholaria B; Perez MAD; Ebens CL; Gale RP; Ganguly S; Gowda L; Grunwald MR; Hashmi S; Hildebrandt GC; Iqbal M; Jamy O; Kharfan-Dabaja MA; Khera N; Lazarus HM; Lin R; Modi D; Nathan S; Nishihori T; Patel SS; Pawarode A; Saber W; Sharma A; Solh M; Wagner JL; Wang T; Williams KM; Winestone LE; Wirk B; Zeidan A; Hourigan CS; Litzow M; Kebriaei P; de Lima M; Page K; Weisdorf DJ
Leukemia; 2023 May; 37(5):1006-1017. PubMed ID: 36310182
[TBL] [Abstract][Full Text] [Related]
15. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
Robin M; Iacobelli S; Koster L; Passweg J; Avenoso D; Wilson KMO; Salmenniemi U; Dreger P; von dem Borne P; Snowden JA; Robinson S; Finazzi MC; Schroeder T; Collin M; Eder M; Forcade E; Loschi M; Bramanti S; Pérez-Simón JA; Czerw T; Polverelli N; Drozd-Sokolowska J; Raj K; Hernández-Boluda JC; McLornan DP
Bone Marrow Transplant; 2024 Mar; ():. PubMed ID: 38491198
[TBL] [Abstract][Full Text] [Related]
16. Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?
Dreger P; Fenske TS; Montoto S; Pasquini MC; Sureda A; Hamadani M;
Biol Blood Marrow Transplant; 2020 Apr; 26(4):e77-e85. PubMed ID: 31917272
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Shadman M; Pasquini M; Ahn KW; Chen Y; Turtle CJ; Hematti P; Cohen JB; Khimani F; Ganguly S; Merryman RW; Yared JA; Locke FL; Ahmed N; Munshi PN; Beitinjaneh A; Reagan PM; Herrera AF; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood; 2022 Mar; 139(9):1330-1339. PubMed ID: 34570879
[TBL] [Abstract][Full Text] [Related]
18. Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?
Meacham LR; George S; Veludhandi A; Pruett MC; Haight AE; Arnold SD; Elchuri S; Stenger E; Krishnamurti L
Transplant Cell Ther; 2023 Aug; 29(8):531.e1-531.e4. PubMed ID: 37169288
[TBL] [Abstract][Full Text] [Related]
19. Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan.
Seydoux C; Uppugunduri CRS; Medinger M; Nava T; Halter J; Heim D; Chalandon Y; Schanz U; Nair G; Cantoni N; Passweg JR; Ansari M
Bone Marrow Transplant; 2023 Jul; 58(7):811-816. PubMed ID: 37085674
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?
Hamadani M; Horowitz MM
J Oncol Pract; 2017 Dec; 13(12):798-806. PubMed ID: 29232542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
